MENLO PARK, Calif., May 6, 2021 / PRNewswire / – LIPAC Oncology LLC., A pharmaceutical company using its liposome-related nanotechnology platform to deliver precisely targeted cancer drugs for the treatment of multiple types of tumors, today announced the appointment of Josh Hamermesh as an independent director.
“Josh is a recognized expert in driving and supporting the growth of innovative companies through his two decades of leadership experience in the biotechnology industry,” said Will robberts, President of LIPAC Oncology. “We welcome Josh to the Board of Directors and look forward to his insights and contributions on corporate and business development, strategy and commercialization as we continue to advance our oncology pipeline and to grow our business. ”
Mr. Hamermesh is currently Chief Commercial Officer at Gamida Cell Ltd. Prior to joining Gamida Cell he was Senior Vice President at Locust Walk Partners, Inc., a strategic partnerships and financing transactions consultancy, where he played a role in instrumental role in directing numerous transactions across a range of therapeutic areas and technologies. Prior to Locust Walk, Mr. Hamermesh served as Vice President, Business and Corporate Development at Infinity Pharmaceuticals, Inc., where he was responsible for the licensing, licensing and alliance management activities of the society. Previously, he served as Senior Vice President, Strategy and Corporate Development at Pervasis Therapeutics, Inc., and also held positions at Molecular Insight Pharmaceuticals, Inc. and Genzyme.
Mr. Hamermesh is currently a member of the board of directors of Neurohealing Pharmaceuticals, Inc. He holds a BS, magna cum laude, Amherst College and an MBA from Harvard Business School.
“I am delighted to join LIPAC Oncology and contribute to the team’s efforts to advance their innovative liposome-related nanotechnology platform and address the unmet needs of patients with intracavitary cancers,” said Mr. Hamermesh. “This is an exciting time for the company as they build on the momentum of a successful FDA Type B meeting and move the program forward into a phase 2b Study of LiPax for the treatment of muscle non-invasive bladder cancer. ”
LiPax is a precision taxane, delivered locally 2b development for intravesical instillation in the treatment of muscular non-invasive bladder cancer (NMIBC). Its liposome-linked nanotechnology platform enables targeted tissue penetration without systemic exposure, toxicity or chemotherapy-related side effects. NMIBC is the leading program with additional orphan indications in urothelial upper tract cancer (UTUC), peritoneal and ovarian cancers, and chest cancers (mesothelioma and malignant pleural effusion). LiPax is designed to improve the level of care for endoscopic outpatient tumor ablation followed by intravesical instillation using a standard urinary catheter. LIPAC Oncology has completed a Phase 2a clinical trial August 2020 and intends to launch a phase 2b study in the second half of 2021 to further research LiPax in the treatment of this condition.
About LIPAC Oncology LLC
LIPAC Oncology is a pharmaceutical company focused on advancing the development of novel experimental therapies to treat intracavitary cancers. Its precision liposome-related nanotechnology platform targets local liposomal delivery of taxanes for the treatment of multiple tumor types. LiPax, its leading experimental candidate for the treatment of muscle non-invasive bladder cancer, is in phase 2b development. The company’s pipeline includes several orphan indications based on the established LiPax formulation. For more information, visit lipaconcology.com.
Sherri spear, 212-600-1902
Leo vartorella, 212-600-1902
SOURCE LIPAC Oncology LLC